治疗前NUDT15药物遗传学检测预防硫嘌呤诱导骨髓抑制的临床效用与成本效益:英国NIHR炎症性肠病生物资源库内的基因型优先反向表型队列研究
该研究基于英国NIHR炎症性肠病生物资源库,采用回顾性病例匹配队列设计,评估治疗前NUDT15药物遗传学检测的临床效用与成本效益。结果显示携带NUDT15变异等位基因与严重骨髓抑制相关(11.3% vs 0.95%,p<0.001),LAMP检测与Sanger测序完全一致(n=154)。作者推荐对亚洲及混合血统患者进行TPMT和NUDT15基因检测。
要点
- 欧洲人NUDT15变异等位基因携带率为1.3%,南亚人为11.7%。
- 严重骨髓抑制与NUDT15变异等位基因携带相关(11.3% vs 0.95%,p<0.001)。
- LAMP检测与Sanger测序完全一致(n=154),且具成本效益。
核心结论
- 作者推荐对亚洲及混合血统患者进行TPMT和NUDT15基因检测。
- 欧洲人中,对TPMT活性降低或功能丧失基因型患者应考虑反射性NUDT15检测。
- 携带>1个NUDT15变异等位基因及同时携带NUDT15和TPMT变异等位基因的患者应避免使用硫嘌呤。
- 携带单个NUDT15变异等位基因的患者,作者推荐硫嘌呤减量(<1 mg/kg/天)并加强血液检测监测。
研究设计与样本
- 回顾性病例匹配队列研究,评估携带与不携带NUDT15功能丧失变异等位基因且接受硫嘌呤治疗患者的严重骨髓抑制发生率。
- 研究嵌套于英国NIHR炎症性肠病生物资源库内。
主要发现
- 欧洲人中NUDT15变异等位基因携带率为1.3%,南亚人中为11.7%。
- 严重骨髓抑制与NUDT15变异等位基因携带相关(11.3% vs 0.95%;p<0.001)。
- 携带单个*3、*6或*9变异等位基因与更短的严重骨髓抑制发生时间相关。
- 在欧洲人和南亚人中,为预防骨髓抑制所需基因检测人数分别为786和23。
- LAMP检测变异识别与Sanger测序完全一致(n=154)。
关键数值与推荐
- 严重骨髓抑制发生率:NUDT15变异等位基因携带者11.3% vs 非携带者0.95%(p<0.001)。
- 欧洲人NUDT15变异等位基因携带率1.3%,南亚人11.7%。
- 预防骨髓抑制所需基因检测人数:欧洲人786,南亚人23。
- LAMP检测与Sanger测序一致性:n=154,完全一致。
临床怎么用
- 作者推荐对亚洲及混合血统患者进行TPMT和NUDT15基因检测。
- 欧洲人中,对TPMT活性降低或功能丧失基因型患者应考虑反射性NUDT15检测。
- 携带>1个NUDT15变异等位基因及同时携带NUDT15和TPMT变异等位基因的患者应避免使用硫嘌呤。
- 携带单个NUDT15变异等位基因的患者,作者推荐硫嘌呤减量(<1 mg/kg/天)并加强血液检测监测。
- LAMP检测可改善硫嘌呤给药安全性,并通过减少无风险变异患者硫嘌呤血液监测的频率和成本而具成本效益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical utility and cost-effectiveness of pre-thiopurine NUDT15 pharmacogenetic testing in European and admixed populations are unknown. AIMS: To report the prevalence, penetrance, expressivity, and pathogenicity of NUDT15 variant allele carriage and the diagnostic accuracy and cost-effectiveness of an inexpensive loop-mediated isothermal amplification (LAMP) test. METHODS: Retrospective case-matched cohort study of rates of severe myelosuppression in patients with and without loss-of-function NUDT15 variant allele(s) treated with a thiopurine. RESULTS: Overall, 1.3% of Europeans and 11.7% of South Asians carried a variant allele. Severe myelosuppression was associated with NUDT15 variant allele carriage (11.3% vs 0.95%; p < 0.001). Carriage of a single *3, *6 or *9 variant allele was associated with a shorter time to severe myelosuppression. Numbers needed to genotype to prevent myelosuppression in Europeans and South Asians were 786 and 23. Variant calling using the LAMP assay was fully concordant with Sanger sequencing (n = 154). It improved the safety of thiopurine dosing and was cost-effective when used to reduce the frequency and cost of thiopurine blood monitoring for patients without risk variants. CONCLUSION: We recommend TPMT and NUDT15 genetic testing in patients of Asian and admixed ancestry. In Europeans, reflex NUDT15 testing should be considered in patients with reduced TPMT activity or loss-of-function genotype. Thiopurines should be avoided in patients with > 1 NUDT15 variant allele and in patients with both NUDT15 and TPMT variant alleles. In patients with a single NUDT15 variant allele, we recommend thiopurine dose reduction (< 1 mg/kg/day) and intensified blood test monitoring.
引用
- Roberts C, Peters J, Sazonvos A, et al. Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource. Aliment Pharmacol Ther. 2025. PMID: 40548539. doi:10.1111/apt.70232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。